These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infection in children in France. The Société de Néphrologie Pédiatrique. Decludt B; Bouvet P; Mariani-Kurkdjian P; Grimont F; Grimont PA; Hubert B; Loirat C Epidemiol Infect; 2000 Apr; 124(2):215-20. PubMed ID: 10813145 [TBL] [Abstract][Full Text] [Related]
16. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195 [TBL] [Abstract][Full Text] [Related]
17. Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites. Nelson JM; Griffin PM; Jones TF; Smith KE; Scallan E Clin Infect Dis; 2011 May; 52(9):1130-2. PubMed ID: 21467017 [TBL] [Abstract][Full Text] [Related]
18. Isolation of an Escherichia coli O157:H7 strain producing Shiga toxin 1 but not Shiga toxin 2 from a patient with hemolytic uremic syndrome in Korea. Kim YB; Okuda J; Matsumoto C; Morigaki T; Asai N; Watanabe H; Nishibuchi M FEMS Microbiol Lett; 1998 Sep; 166(1):43-8. PubMed ID: 9741083 [TBL] [Abstract][Full Text] [Related]
19. Hemolytic uremic syndrome and diarrhea in Argentine children: the role of Shiga-like toxins. Lopez EL; Diaz M; Grinstein S; Devoto S; Mendilaharzu F; Murray BE; Ashkenazi S; Rubeglio E; Woloj M; Vasquez M J Infect Dis; 1989 Sep; 160(3):469-75. PubMed ID: 2668430 [TBL] [Abstract][Full Text] [Related]
20. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues. Karmali MA J Infect Dis; 2004 Feb; 189(3):355-9. PubMed ID: 14745691 [No Abstract] [Full Text] [Related] [Next] [New Search]